Vimal Mehta, CEO and President at BioXcel Therapeutics, Inc. (BTAI), sold 19,419 shares at $1.09 ($21K) on 2026-05-20, disclosed to the SEC on 2026-05-22.
Scheduled sale ($21k) by CEO and President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BTAI | SELL | 2024-06-18 | $3K | — | Filing → |
| BTAI | SELL | 2024-04-08 | $14K | — | Filing → |
| BTAI | SELL | 2023-06-16 | $2.5M | — | Filing → |